REUVENI; Hadas

Patent Applications and Registrations

Patent applications and USPTO patent grants for REUVENI; Hadas.The latest application filed is for "combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer".

Company Profile

3.13.15

REUVENI; Hadas - Har Adar IL
Reuveni; Hadas - D.N. Harei Yehuda IL
Reuveni; Hadas - Yehuda IL
Reuveni, Hadas - Mevaseret Ziyyon IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combinations Of Irs/stat3 Dual Modulators And Anti-cancer Agents For Treating Cancer App 20210220297 - REUVENI; Hadas ; et al.	2021-07-22
Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer Grant 10,912,745 - Reuveni , et al. February 9, 2	2021-02-09
Combinations Of Irs/stat3 Dual Modulators And Anti Pd-1/pd-l1 Antibodies For Treating Cancer App 20200369607 - REUVENI; Hadas ; et al.	2020-11-26
IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases Grant 10,188,659 - Reuveni , et al. Ja	2019-01-29
Igf-1r Signaling Pathway Inhibitors Useful In The Treatment Of Neurodegenerative Diseases App 20180064725 - REUVENI; Hadas ; et al.	2018-03-08
Combinations Of Irs/stat3 Dual Modulators And Anti-cancer Agents For Treating Cancer App 20180028475 - REUVENI; Hadas ; et al.	2018-02-01
Pro-angiogenic peptides and peptide conjugates Grant 9,873,724 - Ben-Sasson , et al. January 23, 2	2018-01-23
IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases Grant 9,770,454 - Reuveni , et al. September 26, 2	2017-09-26
Pro-angiogenic Peptides And Peptide Conjugates App 20160333070 - BEN-SASSON; Shmuel ; et al.	2016-11-17
Igf-1r Signaling Pathway Inhibitors Useful In The Treatment Of Neurodegenerative Diseases App 20160158243 - REUVENI; Hadas ; et al.	2016-06-09
2-(2-phenylethenyl) 1,3-benzodiazepine derivatives useful for the treatment of cancer Grant 9,073,880 - Reuveni , et al. July 7, 2	2015-07-07
Modulators of protein kinase signaling Grant 8,637,575 - Reuveni , et al. January 28, 2	2014-01-28
Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes Grant 8,575,307 - Shafrir , et al. November 5, 2	2013-11-05
2-(2-phenylethenyl) 1,3-benzodiazepine Compounds Useful For The Treatment Of Cancer App 20130274251 - Reuveni; Hadas ; et al.	2013-10-17
Novel Protein Kinase Modulators And Therapeutic Uses Thereof App 20120083528 - Reuveni; Hadas ; et al.	2012-04-05
Protein kinase modulators and therapeutic uses thereof Grant 8,058,309 - Reuveni , et al. November 15, 2	2011-11-15
Novel Modulators Of Protein Kinase Signaling App 20110105618 - Reuveni; Hadas ; et al.	2011-05-05
Protein Kinase C Inhibitors for Prevention of Insulin Resistance and Type 2 Diabetes App 20100216701 - Shafrir; Eleazar ; et al.	2010-08-26
Short peptides from the `2.sup.nd loop` of 7 transmembrane receptor which selectively modulate signal transduction Grant 7,683,031 - Ben-Sasson , et al. March 23, 2	2010-03-23
Novel Protein Kinase Modulators And Therapeutic Uses Thereof App 20100056635 - Reuveni; Hadas ; et al.	2010-03-04
Short peptides from the '2nd loop' of 7 transmembrane receptor which selectively modulate signal transduction App 20060257869 - Ben-Sasson; Shmuel ; et al.	2006-11-16
Protein kinase inhibitors Grant 6,949,565 - Livnah , et al. September 27, 2	2005-09-27
Treatment of cancer App 20040121952 - Ben-Sasson, Shmuel ; et al.	2004-06-24
Protein kinase inhibitors App 20040019077 - Livnah, Nurit ; et al.	2004-01-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.